Back to results
US 2026/0209775 A1Published application
Antisense oligonucleotides targeting ezh2 splicing and their use for treating cancer and kidney disease
AssigneeASOcura Pharmaceuticals Suzhou Co., Ltd.
InventorYimin HUA
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the field of medicine. In particular, it relates to novel antisense oligonucleotides that promote exon 14 skipping in the EZH2 gene, and their use in the treatment of cancer and other diseases.
Claims20
An antisense oligonucleotide of about 10 to about 30 nucleotides in length comprising all or a portion of a sequence selected from the group consisting of (from 5′ to 3′):
- SEQ ID NO:
- 1
- CAAGGCTGCCGTGGATGATCACAG;
- SEQ ID NO:
- 2
- CTGCCGTGGATGATCACAGG;
- SEQ ID NO:
- 3
- GCTGCCGTGGATGATCACAG;
- SEQ ID NO:
- 4
- GGCTGCCGTGGATGATCACA;
- SEQ ID NO:
- 5
- AGGCTGCCGTGGATGATCAC;
- SEQ ID NO:
- 6
- AAGGCTGCCGTGGATGATCA;
- SEQ ID NO:
- 7
- CAAGGCTGCCGTGGATGATC;
- SEQ ID NO:
- 8
- ACAAGGCTGCCGTGGATGAT;
- SEQ ID NO:
- 9
- CACAAGGCTGCCGTGGATGA;
- SEQ ID NO:
- 10
- TCACAAGGCTGCCGTGGATG;
- SEQ ID NO:
- 11
- GTCACAAGGCTGCCGTGGAT;
- SEQ ID NO:
- 12
- TGTCACAAGGCTGCCGTGGA;
- SEQ ID NO:
- 13
- TGCTATCACACAAGGGCACG;
- SEQ ID NO:
- 14
- TGTGCTATCACACAAGGGCA;
- SEQ ID NO:
- 15
- TTGTGCTATCACACAAGGGC;
- SEQ ID NO:
- 16
- TTTGTGCTATCACACAAGGG;
- SEQ ID NO:
- 17
- ATTTTGTGCTATCACACAAG;
- SEQ ID NO:
- 18
- AATTTTGTGCTATCACACAA;
- SEQ ID NO:
- 20
- TTAGAGGAGCCGTCTGAGTA;
- SEQ ID NO:
- 21
- TAGTTGTAAACATGGTTAGA;
- SEQ ID NO:
- 23
- TGATCACAGGGTTGATAGTT;
- SEQ ID NO:
- 24
- GGGCACGAACTGTCACAAGG;
- SEQ ID NO:
- 32
- TTTTGTGCTATCACACAAGG;
- SEQ ID NO:
- 33
- GCCGTGGATGATCACAGGGTT;
- SEQ ID NO:
- 34
- TGCCGTGGATGATCACAGGGT;
- SEQ ID NO:
- 35
- CTGCCGTGGATGATCACAGGG;
- SEQ ID NO:
- 36
- GCTGCCGTGGATGATCACAGG;
- SEQ ID NO:
- 37
- GGCTGCCGTGGATGATCACAG;
- SEQ ID NO:
- 38
- AGGCTGCCGTGGATGATCACA;
- SEQ ID NO:
- 39
- AAGGCTGCCGTGGATGATCAC;
- SEQ ID NO:
- 40
- CAAGGCTGCCGTGGATGATCA;
- SEQ ID NO:
- 41
- TGCCGTGGATGATCACAGGGTT;
- SEQ ID NO:
- 42
- CTGCCGTGGATGATCACAGGGT;
- SEQ ID NO:
- 43
- GCTGCCGTGGATGATCACAGGG;
- SEQ ID NO:
- 44
- GGCTGCCGTGGATGATCACAGG;
- SEQ ID NO:
- 45
- AGGCTGCCGTGGATGATCACAG;
- SEQ ID NO:
- 46
- AAGGCTGCCGTGGATGATCACA;
- SEQ ID NO:
- 47
- CAAGGCTGCCGTGGATGATCAC;
- SEQ ID NO:
- 49
- GCTGCCGTGGATGATCACAGGGT;
- SEQ ID NO:
- 50
- GGCTGCCGTGGATGATCACAGGG;
- SEQ ID NO:
- 51
- AGGCTGCCGTGGATGATCACAGG;
- SEQ ID NO:
- 52
- AAGGCTGCCGTGGATGATCACAG;
- SEQ ID NO:
- 53
- CAAGGCTGCCGTGGATGATCACA;
- SEQ ID NO:
- 54
- GCTGCCGTGGATGATCACAGGGTT;
- SEQ ID NO:
- 55
- GGCTGCCGTGGATGATCACAGGGT;
- SEQ ID NO:
- 56
- AGGCTGCCGTGGATGATCACAGGG;
- SEQ ID NO:
- 57
- AAGGCTGCCGTGGATGATCACAGG;
- SEQ ID NO:
- 58
- GGCTGCCGTGGATGATCACAGGGTT;
- SEQ ID NO:
- 59
- AGGCTGCCGTGGATGATCACAGGGT;
- SEQ ID NO:
- 60
- AAGGCTGCCGTGGATGATCACAGGG;
- SEQ ID NO:
- 61
- CAAGGCTGCCGTGGATGATCACAGG;
- SEQ ID NO:
- 62
- AGGCTGCCGTGGATGATCACAGGGTT;
- SEQ ID NO:
- 63
- AAGGCTGCCGTGGATGATCACAGGGT;
- SEQ ID NO:
- 64
- CAAGGCTGCCGTGGATGATCACAGGG;
- SEQ ID NO:
- 65
- AAGGCTGCCGTGGATGATCACAGGGTT;
- SEQ ID NO:
- 66
- CAAGGCTGCCGTGGATGATCACAGGGT;
- or
- SEQ ID NO:
- 67
- CAAGGCTGCCGTGGATGATCACAGGGTT.
169 more elements
Dependencies are inferred from the claim text.